ASTELLAS PHARMA
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 223
- Registration Number
- NCT01745094
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 163
- Registration Number
- NCT01742585
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 105
- Registration Number
- NCT01742611
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 151
- Registration Number
- NCT01736423
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 20
- Registration Number
- NCT01737268
- Locations
- π―π΅
Site JP00027, Tokyo, Japan
π―π΅Site JP00017, Kanagawa, Japan
π―π΅Site JP00021, Tokyo, Japan
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 172
- Registration Number
- NCT01725282
A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 431
- Registration Number
- NCT01725308
- Locations
- π―π΅
Site JP00009, Chiba, Japan
π―π΅Site JP00037, Fukuoka, Japan
π―π΅Site JP00038, Fukuoka, Japan
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 559
- Registration Number
- NCT01714843
A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 56
- Registration Number
- NCT01675518
A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01674777
Β© Copyright 2024. All Rights Reserved by MedPath